Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma

The phase 3 IMROZ study randomly assigned 446 patients 18 to 80 years of age with newly diagnosed multiple myeloma who were ineligible to undergo transplantation to receive either isatuximab plus bortezomib, lenalidomide, and dexamethasone (VRd) or VRd alone. At a median follow-up of 59.7 months, the estimated progression-free survival at 60 months was 63.2% in the isatuximab-VRd group, as compared with 45.2% in the VRd group. The percentage of patients with a complete response or better was significantly higher in the isatuximab-VRd group than in the VRd group (74.7% vs. 64.1%), as was the percentage of patients with MRD-negative status and a complete response (55.5% vs. 40.9%).